marg hand agenc find like
initi podium studi newsworthi
margetuximab bla submiss decemb mark import mileston note pr
macrogen look forward work agenc bring margetuximab appropri patient
us impli primari focu patient fcriiia allel line clinic benefit
establish sophia phase program elabor prior note numer os benefit patient
harbor allel probabl artifact outcom second os interim analysi
disclos octob competit landscap bigger headwind vs in-lin read
second interim os updat km curv on-going sabc meet potenti add credenc underli
mechanist differ margetuximab parent trastuzumab especi patient
ff/fv genotyp sophia enrol furthermor highlight exhibit
outcom patient favor allel treat doublet margetuximab plu chemo appear
similar unselect popul treat triplet trastuzumab plu tucatinib plu chemotherapi
suggest numer benefit sophia studi may real given seismic chang
treatment landscap near intermedi period like approv tucatinib
clariti zymework zyme buy surpris street dim view
margetuximab howev believ kadcyla could bigger intermedi long-term casualti
approv margetuximab could clinic util ff/fv subject later line
therapi beyond margetuximab like initi two addit registr studi
frontlin squamou non-squam stage nsclc partnership rate interest
develop view
studi like take flight signifi increas
confid activ profil phase studi
combin platinum-bas chemotherapi patient nsclc expect enrol
patient second phase program chemoradi subject stage
nsclc studi expect enrol particip ratio treat either combin
crt follow consolid therapi treatment group placebo combin
crt follow consolid therapi placebo placebo group
time revisit head independ street bearish view margetuximab
like initi registr direct studi flotetzumab primari refractori aml
flotetuzumab reinforc tme base sensit primari refractori aml recent
initi global phase mahogani program frontlin gastric gastroesophag junction cancer
combin margetuximab checkpoint inhibitor detail studi disclos press releas
octob refer note matur gc data esmo set stage immin initi
multi-arm mahogani registr program front-lin phase combin studi emoblituzumab
scchn prior bispecif program enrol patient
across nine indic base manag commentari activ multipl tumor type post-
set data expect pipelin program expand upon
target includ bispecif rate partner
midst three pivot studi highlight like initi two addit program potenti
compel reason revisit stock head view
definit distribut analyst rate analyst certif disclosur pleas refer page report
exhibit comparison sophia
ff fv genotyp
valuat reiter buy rate target base dcf-driven sum-
of-the-part analysi dcf driven beta termin growth rate risk premium
calcul wacc tax rate begin fy margetuximab
flotetuzumab togeth repres full target risk potenti
incur invest stock includ clinic develop financi regulatori reimburs
commerci
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak
pleas let us know email repli delet system may copi
messag disclos content anyon integr secur messag guarante
internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return
given equiti measur rel basi compani sector price object
calcul estim potenti movement price given equiti could reach provid certain target
met defin time horizon price object subject extern factor includ industri event market
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index
compris common stock compani within sector
rate price target histori inc mgnx-u
rate price target histori inc sgen-u
rate price target histori zymework inc zyme-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit
placement secur act financi advisor and/or provid corpor financ capit markets-rel
servic compani one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
debjit chattopadhyay earl desouza certifi view express report accur reflect
person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report
neither member household offic director advisori board member compani
none research analyst research analyst household financi interest secur
macrogen inc inc zymework inc includ without limit option right warrant
futur long short posit
novemb neither firm affili benefici class common equiti
secur inc inc zymework inc
neither research analyst firm know reason know materi conflict interest
time public research report
research analyst princip respons prepar report receiv compens base
upon specif invest bank servic transact compens base factor includ total
revenu profit firm substanti portion deriv invest bank servic
firm affili receiv compens seattl genet inc zymework inc invest
bank servic within twelv month seek compens compani mention report
invest bank servic within three month follow public research report
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic
within three month follow public research report
 wainwright co llc manag co-manag public offer secur inc
firm make market inc inc zymework inc date
research report
secur compani discuss report may unsuit investor depend specif
invest object financi posit past perform guarante futur result report offer
inform purpos constitut offer solicit buy sell secur discuss
herein jurisdict would prohibit research report intend provid tax advic
use provid tax advic person electron version wainwright co llc research report
made avail client simultan part report may reproduc form without express
permiss wainwright co llc addit inform avail upon request
 wainwright co llc provid individu tailor invest advic research report research
report intend provid person invest advic take account specif invest
object financi situat particular need specif person investor seek financi advic
regard appropri invest financi instrument implement invest strategi discuss
recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written
market commentari trade strategi reflect opinion contrari opinion express research
 wainwright co llc affili offic director employe exclud analyst time
time long short posit act princip buy sell secur deriv includ option
warrant thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani
industri secur discuss report opinion estim includ report constitut analyst
judgment date report subject chang without notic
secur financi instrument discuss research report may lose valu insur
feder deposit insur corpor subject invest risk includ possibl loss princip
